Results 11 to 20 of about 2,263,596 (244)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +3 more sources
Introduction to Antibody-Drug Conjugates [PDF]
Antibodies, 2021 Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a monoclonal antibody is linked to a small molecule drug with a stable linker.
Mark C. Pettinato
doaj +4 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez +3 more
doaj +5 more sources
Antibody–Drug Conjugates for Cancer Therapy [PDF]
Biomedicines, 2016 Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell.
Adam C. Parslow +4 more
doaj +6 more sources
Pharmaceutics, 2023 Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising ...
Lal Bahadur Pal +3 more
doaj +2 more sources
Antibody drug conjugates in the clinic
Bioengineering & Translational MedicineAntibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an antibody to enhance their targeted delivery to tumors, represent a significant advancement in cancer therapy.
Edidiong Udofa +3 more
doaj +3 more sources
Antibody–Drug Conjugates [PDF]
Bioconjugate Chemistry, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Li, Peng, Xiaoyuan, Chen
openaire +5 more sources
Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates [PDF]
, 2021 With the advent of chemical strategies that allow the design of smart bioconjugates, peptide- and protein-drug conjugates are emerging as highly efficient therapeutics to overcome limitations of conventional treatment, as exemplified by antibody-drug ...
Seah Ling, Kuan +8 more
core +2 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
openaire +5 more sources
Galactose Oxidase Enables Modular Assembly of Conjugates from Native Antibodies with High Drug-to-Antibody Ratios [PDF]
, 2021 The potential of antibody conjugates with high drug loading in anticancer therapy has recently been highlighted by the approval of Trastuzumab deruxtecan and Sacituzumab govitecan.
William, Goundry +7 more
core +2 more sources